BioRadar Blog
Biotech trading insights, PDUFA analysis, and market intelligence.
SELLAS’s REGAL Trial Met Its Survival Goal: What the Topline Shows and What Is Still Missing
SELLAS Life Sciences said on November 17, 2026 that its Phase 3 REGAL trial met its primary endpoint. Patients with acute myeloid leukemia who received galinpepimut-S (GPS) lived a median…
Read article →Biotech Catalysts This Week: 4 Trial Completions, 15 Earnings Reports and 10 New Financings (Nov 15-22, 2026)
Biotech catalysts, Nov 15 to Nov 22, 2026: no FDA decision dates, 4 Phase 2 or 3 trials reaching primary completion, 15 earnings reports and 10 new…
Read article →Biotech Catalysts This Week: 3 FDA Decisions, 3 Trial Completions and 15 Earnings Reports (Nov 8-15, 2026)
Biotech catalysts, Nov 8 to Nov 15, 2026: 3 FDA decision dates, 3 Phase 2 or 3 trials reaching primary completion, 15 earnings reports and 10 new financing…
Read article →Biotech Catalysts This Week: 12 Trial Completions, 9 Earnings Reports and 10 New Financings (Nov 1-8, 2026)
Biotech catalysts, Nov 1 to Nov 8, 2026: no FDA decision dates, 12 Phase 2 or 3 trials reaching primary completion, 9 earnings reports and 10 new financing…
Read article →Biotech Catalysts This Week: 2 FDA Decisions, 12 Trial Completions and 2 Earnings Reports (Oct 25-Nov 1, 2026)
Biotech catalysts, Oct 25 to Nov 1, 2026: 2 FDA decision dates, 12 Phase 2 or 3 trials reaching primary completion, 2 earnings reports and 10 new financing…
Read article →FDA Turns Down Ivonescimab: What Summit’s Complete Response Letter Means
The FDA rejected ivonescimab for lack of a significant survival benefit. What Summit's complete response letter says, its cash, HARMONi-3 and three scenarios.
Read article →Biotech Catalysts This Week: 4 Trial Completions and 9 New Financings (Oct 18-25, 2026)
Biotech catalysts, Oct 18 to Oct 25, 2026: no FDA decision dates, 4 Phase 2 or 3 trials reaching primary completion and 9 new financing filings.
Read article →How Big Can Anktiva Get? ImmunityBio’s Market After the Papillary Approval
How big can Anktiva get after the FDA's papillary approval? ImmunityBio's US sales, a step-by-step market estimate, competitors and financing risks.
Read article →Biotech Catalysts This Week: 1 FDA Decision, 1 Trial Completion and 8 New Financings (Oct 11-18, 2026)
Biotech catalysts, Oct 11 to Oct 18, 2026: 1 FDA decision date, 1 Phase 2 or 3 trial reaching primary completion and 8 new financing filings.
Read article →PDS Biotech (PDSB) After the Soon-Shiong PIPE: What the Filings and Trials Show About PDS0301, and What Could Come Next
What PDS Biotech's filings and trials show about PDS0301 (IL-12), Patrick Soon-Shiong's 19.9% stake and the talked-about Anktiva combination.
Read article →